Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Merck exec joins Novartis to helm oncology unit

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Bayer drafts Otsuka exec to lead pharma biz to big growth

Bayer's pharma division has a new president with a big task ahead of him. A week after the company announced its current leader, Andreas Fibig, would jump ship, Bayer says it's chosen an Otsuka Pharmaceutical executive to take the post.

Bayer CEO's long goodbye: Dekkers to depart at end of 2016

Marijn Dekkers has set his own expiration date as Bayer CEO. The German conglomerate said Dekkers would leave at the end of 2016, giving him 7 years in the top slot. It's the latest in a series of executive moves at Bayer, whose HealthCare division has been outperforming the rest of the company.

UPDATED: In management reorg, Teva taps Actavis alum to helm new global generics unit

Teva Pharmaceutical Industries CEO Erez Vigodman has been a busy man. So busy, in fact, it seems the company's press releases barely keep up with him. Today's announcement: Vigodman has overhauled Teva's management structure, winnowing out 6 executive jobs and creating two worldwide divisions. And he recruited a pharma-industry vet to take the helm of one of them.

Novartis nabs Merck exec Bruno Strigini to head up oncology business

Novartis wooed one of Merck & Co.'s top executives to take the helm at its oncology unit.

Metabolic disease, cardio expert joins Pfizer's R&D team

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Former CDER official joins Greenleaf Health, biosimilars experience in tow

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Who's going to run Celgene when Hugin hangs it up?

With Celgene CEO Bob Hugin working through his 15th year at the company, an internal race to spot his eventual successor appears to be in progress, and the Big Biotech's latest round of promotions provides some clues to its future leadership.

Forest CEO Saunders to lead combined company after Actavis buyout

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Prepping for $25B merger, Actavis taps Forest CEO Saunders to lead combined company

When Actavis CEO Paul Bisaro announced his big buyout of Forest Laboratories, he sketched a picture of a brand-plus-generic powerhouse with lower costs and bigger revenue prospects. Now, it will be Forest CEO Brent Saunders who colors in those lines as chief executive of the merged company.